What is the appropriate evaluation and management for a patient with low testosterone and normal luteinizing hormone (LH) and follicle‑stimulating hormone (FSH)?

Low Testosterone with Normal LH and FSH: Secondary Hypogonadism Evaluation and Management

This presentation indicates secondary (central) hypogonadism—a hypothalamic-pituitary dysfunction where the pituitary fails to appropriately elevate LH/FSH despite low testosterone, requiring further evaluation to identify the underlying cause before initiating treatment.

Diagnostic Confirmation

First, confirm true hypogonadism exists:

• Verify with two separate early morning total testosterone measurements below 300 ng/dL 1
• Both samples should use the same laboratory and methodology
• Symptoms must be present—low testosterone alone without clinical manifestations does not warrant treatment 2, 1
• Relevant symptoms include: reduced libido, erectile dysfunction, fatigue, reduced energy/endurance, decreased work performance, depression, poor concentration, and infertility 1

The normal LH and FSH in the setting of low testosterone is paradoxical—the pituitary should be driving these gonadotropins higher to compensate. This "inappropriately normal" response defines secondary hypogonadism 2.

Mandatory Etiologic Workup

You must investigate the cause of hypothalamic-pituitary dysfunction 2. This is not optional—secondary hypogonadism can signal serious underlying pathology:

Critical evaluations to perform:

• MRI of the pituitary/hypothalamus to exclude:

  • Pituitary adenomas (prolactinoma most common)
  • Craniopharyngiomas
  • Other mass lesions causing compression
  • Empty sella syndrome

• Prolactin level—hyperprolactinemia commonly suppresses GnRH pulsatility

• Iron studies—hemochromatosis causes hypogonadotropic hypogonadism

• Morning cortisol and thyroid function—assess for additional pituitary hormone deficiencies

• Medication review—chronic opioids, corticosteroids, and anabolic steroids suppress the hypothalamic-pituitary axis 1

• Screen for systemic illness—chronic kidney disease, HIV/AIDS, obesity, and type 2 diabetes are associated with secondary hypogonadism 1, 3

• Visual field testing if pituitary mass suspected (bitemporal hemianopsia suggests chiasmal compression) 1

Treatment Decision Algorithm

If reversible cause identified:

• Treat the underlying condition first (e.g., discontinue offending medications, treat hyperprolactinemia, address obesity/metabolic syndrome)
• Recheck testosterone after addressing reversible factors

If irreversible secondary hypogonadism confirmed:

For men desiring fertility preservation:

• Do NOT use testosterone therapy—it will further suppress spermatogenesis 2
• Consider human chorionic gonadotropin (hCG) with or without FSH to stimulate endogenous testosterone and maintain fertility 4
• Alternatively, selective estrogen receptor modulators (SERMs) like clomiphene citrate can raise endogenous testosterone while preserving fertility 4

For men not concerned with fertility:

• Initiate testosterone replacement therapy targeting mid-normal range testosterone levels 2
• Formulation choice depends on patient preference, cost, and tolerability

Contraindications to Testosterone Therapy

Absolute contraindications 2:

• Planning fertility in near term
• Breast or prostate cancer
• PSA >4 ng/mL (or >3 ng/mL in high-risk men without urologic evaluation)
• Palpable prostate nodule
• Hematocrit >50%
• Untreated severe obstructive sleep apnea
• Severe lower urinary tract symptoms
• Uncontrolled heart failure
• MI or stroke within 6 months
• Thrombophilia

Monitoring on Testosterone Therapy

First year monitoring protocol 2:

• Testosterone levels at 3-6 months, then annually
• Hematocrit at 3-6 months, then annually (discontinue if >54%)
• PSA and digital rectal exam at 3-6 months, then annually in men >40 years
• Symptom assessment at each visit
• Bone density if hypogonadism was prolonged

Critical Pitfalls

The most common error is initiating testosterone without measuring LH/FSH 5—a 2015 study found only 12% of men had gonadotropins measured before starting therapy. This misses the opportunity to identify and treat reversible causes of secondary hypogonadism.

The second major pitfall is treating asymptomatic men with borderline testosterone—up to 25% of men on testosterone therapy do not meet diagnostic criteria 1. Symptoms must accompany low testosterone levels.

Do not routinely screen asymptomatic men for testosterone deficiency 2—this leads to overdiagnosis and inappropriate treatment.